Precision BioSciences, Inc. Common Stock

DTILNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
6.14 USD
↘ 0.17 (2.69%)🟢LIVE (AS OF 02:13 PM EDT)
🟢Market: OPEN

DTIL is currently priced at $6.14. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. DTIL is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Oct 5, 2026.

Open?$6.36
High?$6.46
Low?$6.10
Prev. Close?$6.31
Volume?126.3K
Avg. Volume?257.3K
VWAP?$6.26
Rel. Volume?0.49x
Bid / Ask
Bid?$6.22 × 100
Ask?$6.24 × 200
Spread?$0.02
Midpoint?$6.23
Valuation & Ratios
Market Cap?174.2M
Shares Out?27.6M
Float?24.3M
Float %?94.0%
P/E Ratio?N/A
P/B Ratio?3.85
EPS?-$2.09
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Clinical-Stage Platforms
Employees
67
Market Cap
174.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.precisionbiosciences.com
Listed
2019-03-28
Address
302 EAST PETTIGREW STREET
DURHAM, NC 27701
Phone: 919-314-5512
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
33
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.36Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?9.16%Elevated
Short Interest?2.2M
Days to Cover?10.6
Free Float24.3M
Avg Daily Volume210.7K
Settlement Date2026-09-15
Financial Health
Current Ratio?12.82Strong
Quick Ratio?12.82Strong
Cash Ratio?12.06Strong
Debt/Equity?0.50Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
75/100
P/E?
N/A▾
P/B?
Peers
100
S&P
46
3.85FAIR▾
P/S?
Peers
100
S&P
28
5.09FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.3CHEAP▾
EV/Sales?
Peers
100
S&P
57
3.23FAIR▾
Returns & Efficiency
ROE?
S&P
3
-127.6%WEAK▾
ROA?
S&P
3
-45.9%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$110.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist